

Dry Age Macular Degeneration Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/DF31B2B035A1EN.html>

Date: May 2024

Pages: 136

Price: US\$ 6,499.00 (Single User License)

ID: DF31B2B035A1EN

Abstracts

The 7 major dry age macular degeneration markets are expected to exhibit a CAGR of 4.64% during 2024-2034.

The dry age macular degeneration market has been comprehensively analyzed in IMARC's new report titled "Dry Age Macular Degeneration Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Dry age macular degeneration is a common eye disorder that mostly affects individuals upon aging. This condition causes thinning of the macula's inner layers, which are responsible for detail perception as well as central and color visions. In most cases, vision may deteriorate over time and impair one's ability to drive, read, and recognize faces. Individuals suffering from this ailment may experience a need for brighter light when reading or doing close work, blank or dark spots in the field of vision, increased difficulty adapting to low light levels, straight lines looking crooked or wavy, blurred or diminished central vision, etc. The diagnosis of dry age macular degeneration typically requires a review of the patient's symptoms, medical history, and dilated eye examination. During an eye workup, the healthcare provider will evaluate characteristic changes or abnormalities in the retina and macula, such as the presence of small yellowish deposits called drusen. Numerous other tests to assess visual function, including fluorescein angiography and optical coherence tomography, are also recommended to diagnose dry age macular degeneration.

The expanding geriatric population, who are more susceptible to the degradation of cells in the macula, thereby resulting in scarring of the retina, is primarily driving the dry age macular degeneration market. Additionally, the increasing prevalence of several associated risk factors, such as smoking, obesity, high blood pressure, an inadequate

diet, etc., is also propelling the market growth. Moreover, the widespread demand for antioxidant vitamins and minerals, including vitamin C and E, beta-carotene, zinc, copper, etc., which reduce cellular damage by deactivating free radicals in the retina, is further creating a positive outlook for the market. Apart from this, the escalating adoption of anti-angiogenic drugs, such as ranibizumab and aflibercept, that can be directly injected into the eye to help slow the progression of abnormal blood vessels and provide symptom relief is acting as another significant growth-inducing factor. Furthermore, the rising utilization of laser photocoagulation therapy owing to its various advantages, including resolution of drusen, prevention of vision loss, and improvement in quality of life for affected people, is expected to drive the dry age macular degeneration market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the dry age macular degeneration market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for dry age macular degeneration and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the dry age macular degeneration market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the dry age macular degeneration market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the dry age macular degeneration market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current dry age macular degeneration marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

How has the dry age macular degeneration market performed so far and how will it

perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the dry age macular degeneration market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the dry age macular degeneration market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of dry age macular degeneration across the seven major markets?

What is the number of prevalent cases (2018-2034) of dry age macular degeneration by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of dry age macular degeneration by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with dry age macular degeneration across the seven major markets?

What is the size of the dry age macular degeneration patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of dry age macular degeneration?

What will be the growth rate of patients across the seven major markets?

Dry Age Macular Degeneration: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for dry age macular degeneration drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc.

related to the dry age macular degeneration market?

What are the key regulatory events related to the dry age macular degeneration market?

What is the structure of clinical trial landscape by status related to the dry age macular degeneration market?

What is the structure of clinical trial landscape by phase related to the dry age macular degeneration market?

What is the structure of clinical trial landscape by route of administration related to the dry age macular degeneration market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 DRY AGE MACULAR DEGENERATION - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 DRY AGE MACULAR DEGENERATION - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 DRY AGE MACULAR DEGENERATION - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights
- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (?2018-2034?)
 - 7.2.4 Epidemiology by Gender (?2018-2034?)
 - 7.2.5 Diagnosed Cases (?2018-2034?)
 - 7.2.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (?2018-2034?)
 - 7.3.4 Epidemiology by Gender (?2018-2034?)
 - 7.3.5 Diagnosed Cases (?2018-2034?)
 - 7.3.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (?2018-2034?)
 - 7.4.4 Epidemiology by Gender (?2018-2034?)
 - 7.4.5 Diagnosed Cases (?2018-2034?)
 - 7.4.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (?2018-2034?)
 - 7.5.4 Epidemiology by Gender (?2018-2034?)
 - 7.5.5 Diagnosed Cases (?2018-2034?)
 - 7.5.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (?2018-2034?)
 - 7.6.4 Epidemiology by Gender (?2018-2034?)
 - 7.6.5 Diagnosed Cases (?2018-2034?)
 - 7.6.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034)

- 7.7.3 Epidemiology by Age (?2018-2034?)
- 7.7.4 Epidemiology by Gender (?2018-2034?)
- 7.7.5 Diagnosed Cases (?2018-2034?)
- 7.7.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (?2018-2034?)
 - 7.8.4 Epidemiology by Gender (?2018-2034?)
 - 7.8.5 Diagnosed Cases (?2018-2034?)
 - 7.8.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (?2018-2034?)
 - 7.9.4 Epidemiology by Gender (?2018-2034?)
 - 7.9.5 Diagnosed Cases (?2018-2034?)
 - 7.9.6 Patient Pool/Treated Cases (?2018-2034?)

8 DRY AGE MACULAR DEGENERATION - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 DRY AGE MACULAR DEGENERATION - UNMET NEEDS

10 DRY AGE MACULAR DEGENERATION - KEY ENDPOINTS OF TREATMENT

11 DRY AGE MACULAR DEGENERATION - MARKETED PRODUCTS

- 11.1 List of Dry Age Macular Degeneration Marketed Drugs Across the Top 7 Markets
 - 11.1.1 Drug Name – Company Name
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results
 - 11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.

12 DRY AGE MACULAR DEGENERATION - PIPELINE DRUGS

12.1 List of Dry Age Macular Degeneration Pipeline Drugs Across the Top 7 Markets

12.1.1 RPESC RPE 4W - Luxa Biotechnology

- 12.1.1.1 Drug Overview
- 12.1.1.2 Mechanism of Action
- 12.1.1.3 Clinical Trial Results
- 12.1.1.4 Safety and Efficacy
- 12.1.1.5 Regulatory Status

12.1.2 AAVCAGsCD59 - Janssen Research & Development

- 12.1.2.1 Drug Overview
- 12.1.2.2 Mechanism of Action
- 12.1.2.3 Clinical Trial Results
- 12.1.2.4 Safety and Efficacy
- 12.1.2.5 Regulatory Status

12.1.3 QA102 - Smilebiotek Zhuhai Limited

- 12.1.3.1 Drug Overview
- 12.1.3.2 Mechanism of Action
- 12.1.3.3 Clinical Trial Results
- 12.1.3.4 Safety and Efficacy
- 12.1.3.5 Regulatory Status

12.1.4 Risuteganib - Allegro Ophthalmics

- 12.1.4.1 Drug Overview
- 12.1.4.2 Mechanism of Action
- 12.1.4.3 Clinical Trial Results
- 12.1.4.4 Safety and Efficacy
- 12.1.4.5 Regulatory Status

12.1.5 CPCB RPE1 - Regenerative Patch Technologies

- 12.1.5.1 Drug Overview
- 12.1.5.2 Mechanism of Action
- 12.1.5.3 Clinical Trial Results
- 12.1.5.4 Safety and Efficacy
- 12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. DRY AGE MACULAR DEGENERATION - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. DRY AGE MACULAR DEGENERATION – CLINICAL TRIAL LANDSCAPE

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

15 DRY AGE MACULAR DEGENERATION - MARKET SCENARIO

- 15.1 Market Scenario - Key Insights
- 15.2 Market Scenario - Top 7 Markets
 - 15.2.1 Dry Age Macular Degeneration - Market Size
 - 15.2.1.1 Market Size (2018-2023)
 - 15.2.1.2 Market Forecast (2024-2034)
 - 15.2.2 Dry Age Macular Degeneration - Market Size by Therapies
 - 15.2.2.1 Market Size by Therapies (2018-2023)
 - 15.2.2.2 Market Forecast by Therapies (2024-2034)
- 15.3 Market Scenario - United States
 - 15.3.1 Dry Age Macular Degeneration - Market Size
 - 15.3.1.1 Market Size (2018-2023)
 - 15.3.1.2 Market Forecast (2024-2034)
 - 15.3.2 Dry Age Macular Degeneration - Market Size by Therapies
 - 15.3.2.1 Market Size by Therapies (2018-2023)
 - 15.3.2.2 Market Forecast by Therapies (2024-2034)
 - 15.3.3 Dry Age Macular Degeneration - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
 - 15.4.1 Dry Age Macular Degeneration - Market Size
 - 15.4.1.1 Market Size (2018-2023)
 - 15.4.1.2 Market Forecast (2024-2034)
 - 15.4.2 Dry Age Macular Degeneration - Market Size by Therapies
 - 15.4.2.1 Market Size by Therapies (2018-2023)
 - 15.4.2.2 Market Forecast by Therapies (2024-2034)
 - 15.4.3 Dry Age Macular Degeneration - Access and Reimbursement Overview
- 15.5 Market Scenario - France
 - 15.5.1 Dry Age Macular Degeneration - Market Size
 - 15.5.1.1 Market Size (2018-2023)
 - 15.5.1.2 Market Forecast (2024-2034)
 - 15.5.2 Dry Age Macular Degeneration - Market Size by Therapies

- 15.5.2.1 Market Size by Therapies (2018-2023)
- 15.5.2.2 Market Forecast by Therapies (2024-2034)
- 15.5.3 Dry Age Macular Degeneration - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
 - 15.6.1 Dry Age Macular Degeneration - Market Size
 - 15.6.1.1 Market Size (2018-2023)
 - 15.6.1.2 Market Forecast (2024-2034)
 - 15.6.2 Dry Age Macular Degeneration - Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (2018-2023)
 - 15.6.2.2 Market Forecast by Therapies (2024-2034)
 - 15.6.3 Dry Age Macular Degeneration - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
 - 15.7.1 Dry Age Macular Degeneration - Market Size
 - 15.7.1.1 Market Size (2018-2023)
 - 15.7.1.2 Market Forecast (2024-2034)
 - 15.7.2 Dry Age Macular Degeneration - Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (2018-2023)
 - 15.7.2.2 Market Forecast by Therapies (2024-2034)
 - 15.7.3 Dry Age Macular Degeneration - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
 - 15.8.1 Dry Age Macular Degeneration - Market Size
 - 15.8.1.1 Market Size (2018-2023)
 - 15.8.1.2 Market Forecast (2024-2034)
 - 15.8.2 Dry Age Macular Degeneration - Market Size by Therapies
 - 15.8.2.1 Market Size by Therapies (2018-2023)
 - 15.8.2.2 Market Forecast by Therapies (2024-2034)
 - 15.8.3 Dry Age Macular Degeneration - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
 - 15.9.1 Dry Age Macular Degeneration - Market Size
 - 15.9.1.1 Market Size (2018-2023)
 - 15.9.1.2 Market Forecast (2024-2034)
 - 15.9.2 Dry Age Macular Degeneration - Market Size by Therapies
 - 15.9.2.1 Market Size by Therapies (2018-2023)
 - 15.9.2.2 Market Forecast by Therapies (2024-2034)
 - 15.9.3 Dry Age Macular Degeneration - Access and Reimbursement Overview

16 DRY AGE MACULAR DEGENERATION - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 DRY AGE MACULAR DEGENERATION MARKET - SWOT ANALYSIS

17.1 Strengths

17.2 Weaknesses

17.3 Opportunities

17.4 Threats

18 DRY AGE MACULAR DEGENERATION MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Dry Age Macular Degeneration Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/DF31B2B035A1EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/DF31B2B035A1EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

